164 related articles for article (PubMed ID: 34785111)
21. Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Piatopoulou D; Avgeris M; Drakaki I; Marmarinos A; Xagorari M; Baka M; Pourtsidis A; Kossiva L; Gourgiotis D; Scorilas A
Ann Hematol; 2018 Jul; 97(7):1169-1182. PubMed ID: 29556721
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
23. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract][Full Text] [Related]
24. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group.
Rau RE; Dai Y; Devidas M; Rabin KR; Zweidler-McKay P; Angiolillo A; Schore RJ; Burke MJ; Salzer WL; Heerema NA; Carroll AJ; Winick NJ; Hunger SP; Raetz EA; Loh ML; Wood BL; Borowitz MJ
Pediatr Blood Cancer; 2021 Apr; 68(4):e28929. PubMed ID: 33559396
[TBL] [Abstract][Full Text] [Related]
26. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.
Ribera JM; Oriol A; Morgades M; Montesinos P; Sarrà J; González-Campos J; Brunet S; Tormo M; Fernández-Abellán P; Guàrdia R; Bernal MT; Esteve J; Barba P; Moreno MJ; Bermúdez A; Cladera A; Escoda L; García-Boyero R; Del Potro E; Bergua J; Amigo ML; Grande C; Rabuñal MJ; Hernández-Rivas JM; Feliu E
J Clin Oncol; 2014 May; 32(15):1595-604. PubMed ID: 24752047
[TBL] [Abstract][Full Text] [Related]
27. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.
Takachi T; Watanabe T; Miyamura T; Moriya Saito A; Deguchi T; Hori T; Yamada T; Ohmori S; Haba M; Aoki Y; Ishimaru S; Sasaki S; Ohshima J; Iguchi A; Takahashi Y; Hyakuna N; Manabe A; Horibe K; Ishii E; Koh K; Tomizawa D
Blood Adv; 2021 Oct; 5(19):3891-3899. PubMed ID: 34500465
[TBL] [Abstract][Full Text] [Related]
29. MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children's Oncology Group trial AALL1231.
Hayashi RJ; Hermiston ML; Wood BL; Teachey DT; Devidas M; Chen Z; Annett RD; Asselin BL; August K; Cho S; Dunsmore KP; Freedman JL; Galardy PJ; Harker-Murray P; Horton TM; Jaju A; Lam A; Messinger YH; Miles RR; Okada M; Patel S; Schafer ES; Schechter T; Shimano KA; Singh N; Steele A; Sulis ML; Vargas SL; Winter SS; Wood C; Zweidler-McKay PA; Loh ML; Hunger SP; Raetz EA; Bollard CM; Allen CE
Blood; 2024 May; 143(20):2053-2058. PubMed ID: 38457359
[TBL] [Abstract][Full Text] [Related]
30. Impact of Minimal Residual Disease Detection by Next Generation Flow Cytometry on Outcome of Egyptian Patients with Acute Lymphoblastic Leukemia.
Algamal RA; Abu Samra NK; Ellashery RA; Abd-EL-Hameed SAE; Shahin DA
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3577-3584. PubMed ID: 37898866
[TBL] [Abstract][Full Text] [Related]
31. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse.
Jacquy C; Delepaut B; Van Daele S; Vaerman JL; Zenebergh A; Brichard B; Vermylen C; Cornu G; Martiat P
Br J Haematol; 1997 Jul; 98(1):140-6. PubMed ID: 9233577
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
33. Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia.
Šálek C; Folber F; Froňková E; Procházka B; Marinov I; Cetkovský P; Mayer J; Doubek M;
Eur J Haematol; 2016 Mar; 96(3):276-84. PubMed ID: 25997106
[TBL] [Abstract][Full Text] [Related]
34. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
35. Eleven-marker 10-color flow cytometric assessment of measurable residual disease for T-cell acute lymphoblastic leukemia using an approach of exclusion.
Tembhare PR; Chatterjee G; Khanka T; Ghogale S; Badrinath Y; Deshpande N; Panda D; Patkar NV; Narula G; Girase K; Verma S; Sanyal M; Sriram HN; Banavali S; Gujral S; Subramanian PG
Cytometry B Clin Cytom; 2021 Jul; 100(4):421-433. PubMed ID: 32812702
[TBL] [Abstract][Full Text] [Related]
36. Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia.
Pushpam D; Rajput N; Chopra A; Vishnubhatla S; Kumari M; Kumar R; Bakhshi S
Pediatr Hematol Oncol; 2019 Apr; 36(3):138-150. PubMed ID: 31046540
[TBL] [Abstract][Full Text] [Related]
37. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of minimal residual disease in adult Egyptian patients with precursor acute lymphoblastic leukemia.
Samra MA; Mahmoud HK; Abdelhamid TM; El Sharkawy NM; Elnahass YH; Elgammal M; Abdelfattah RM; Eid S; Ghaleb FM; Kamel AM
J Egypt Natl Canc Inst; 2013 Sep; 25(3):135-42. PubMed ID: 23932750
[TBL] [Abstract][Full Text] [Related]
39. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D; Moorman AV; Wade R; Hancock J; Tan RM; Bartram J; Moppett J; Schwab C; Patrick K; Harrison CJ; Hough R; Goulden N; Vora A; Samarasinghe S
J Clin Oncol; 2017 Feb; 35(6):660-667. PubMed ID: 28045622
[TBL] [Abstract][Full Text] [Related]
40. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
